ES2135934T3 - Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros. - Google Patents

Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.

Info

Publication number
ES2135934T3
ES2135934T3 ES96937390T ES96937390T ES2135934T3 ES 2135934 T3 ES2135934 T3 ES 2135934T3 ES 96937390 T ES96937390 T ES 96937390T ES 96937390 T ES96937390 T ES 96937390T ES 2135934 T3 ES2135934 T3 ES 2135934T3
Authority
ES
Spain
Prior art keywords
group
ilo
rent
fenile
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96937390T
Other languages
English (en)
Spanish (es)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2135934T3 publication Critical patent/ES2135934T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES96937390T 1995-11-09 1996-11-05 Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros. Expired - Lifetime ES2135934T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ES2135934T3 true ES2135934T3 (es) 1999-11-01

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96937390T Expired - Lifetime ES2135934T3 (es) 1995-11-09 1996-11-05 Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.

Country Status (29)

Country Link
US (1) US5929089A (2)
EP (1) EP0863897B1 (2)
JP (1) JP4263240B2 (2)
CN (1) CN1077891C (2)
AR (1) AR004708A1 (2)
AT (1) ATE181328T1 (2)
AU (1) AU707325B2 (2)
BG (1) BG63463B1 (2)
BR (1) BR9611311A (2)
CA (1) CA2236357C (2)
CO (1) CO4770968A1 (2)
CZ (1) CZ287268B6 (2)
DE (1) DE69602970T2 (2)
EE (1) EE03487B1 (2)
ES (1) ES2135934T3 (2)
GR (1) GR3030823T3 (2)
HU (1) HUP0001168A3 (2)
IL (1) IL124364A (2)
MX (1) MX9803696A (2)
NO (1) NO309606B1 (2)
NZ (1) NZ321626A (2)
PL (1) PL186204B1 (2)
RU (1) RU2167160C2 (2)
SI (1) SI0863897T1 (2)
SK (1) SK282335B6 (2)
TR (1) TR199800827T2 (2)
TW (1) TW371303B (2)
UA (1) UA50748C2 (2)
WO (1) WO1997017345A1 (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
WO1998050383A1 (fr) * 1997-05-06 1998-11-12 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
FR2763068B1 (fr) * 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
CN1269484C (zh) 1998-09-18 2006-08-16 艾尔科实验室公司 用于治疗青光眼的5－羟色胺激活性激动剂
EP1173168A2 (en) * 1999-04-28 2002-01-23 Respiratorius AB Compound for use as a medicament for treatment of disorders involving bronchocontraction
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
CZ2003686A3 (cs) 2000-08-08 2003-08-13 Ortho Mcneil Pharmaceutical, Inc. Neimidazolové aryloxypiperidiny
US6638967B2 (en) 2000-08-08 2003-10-28 Ortho-Mcneil Phamraceutical, Inc. Thiophene of furan pyrrolidine compounds
ATE319696T1 (de) 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
EP1421071B1 (en) 2001-07-02 2009-11-18 High Point Pharmaceuticals, LLC Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
EP1430027B1 (en) 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
DE60234616D1 (de) * 2001-09-14 2010-01-14 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003051352A1 (en) 2001-12-14 2003-06-26 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
RU2499795C2 (ru) 2005-07-04 2013-11-27 Хай Пойнт Фармасьютикалс, ЛЛС Антагонисты гистаминовых н3-рецепторов
WO2007063012A1 (en) * 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
SG163547A1 (en) 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
AP3307A (en) * 2011-09-19 2015-06-30 Suven Life Sciences Ltd Heteroaryl compounds as 5-HT4 receptor ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
CA2116024A1 (en) * 1991-08-20 1993-03-04 Francis David King 5-ht4 receptor antagonists
CA2118812C (en) * 1991-09-12 2006-01-17 Francis David King 5-ht4 receptor antagonists
EP0625149A1 (en) * 1992-02-06 1994-11-23 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
AU7500196A (en) 1997-05-29
CO4770968A1 (es) 1999-04-30
PL186204B1 (pl) 2003-11-28
NZ321626A (en) 1998-10-28
DE69602970T2 (de) 2000-01-20
IL124364A0 (en) 1998-12-06
SK59998A3 (en) 1998-11-04
NO309606B1 (no) 2001-02-26
CZ287268B6 (en) 2000-10-11
UA50748C2 (uk) 2002-11-15
JP4263240B2 (ja) 2009-05-13
NO982092D0 (no) 1998-05-07
SK282335B6 (sk) 2002-01-07
CA2236357A1 (en) 1997-05-15
ATE181328T1 (de) 1999-07-15
JP2000500125A (ja) 2000-01-11
AR004708A1 (es) 1999-03-10
EE9800155A (et) 1998-12-15
CA2236357C (en) 2006-10-17
CN1202169A (zh) 1998-12-16
DE69602970D1 (de) 1999-07-22
HK1016165A1 (en) 1999-10-29
BR9611311A (pt) 1999-06-29
TW371303B (en) 1999-10-01
CZ142198A3 (cs) 1998-08-12
RU2167160C2 (ru) 2001-05-20
EE03487B1 (et) 2001-08-15
AU707325B2 (en) 1999-07-08
IL124364A (en) 2001-08-08
NO982092L (no) 1998-06-29
MX9803696A (es) 1998-09-30
WO1997017345A1 (fr) 1997-05-15
SI0863897T1 (en) 1999-10-31
CN1077891C (zh) 2002-01-16
EP0863897A1 (fr) 1998-09-16
HUP0001168A3 (en) 2001-07-30
BG102412A (en) 1999-08-31
HUP0001168A2 (hu) 2001-04-28
GR3030823T3 (en) 1999-11-30
TR199800827T2 (xx) 1999-02-22
PL326671A1 (en) 1998-10-12
US5929089A (en) 1999-07-27
BG63463B1 (bg) 2002-02-28
EP0863897B1 (fr) 1999-06-16

Similar Documents

Publication Publication Date Title
ES2135934T3 (es) Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.
PA8538301A1 (es) Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas
ES2162933T3 (es) Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft).
PA8491101A1 (es) Derivados de 4-fenil-piridin.
AR035793A1 (es) Compuesto de ciclopropilindol, formulacion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para la preparacion de compuestos intermediarios para su sintesis
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
ES2135414T3 (es) Antagonistas del receptor 5-ht4.
ES2157224T3 (es) Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1).
FI75559C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-aminopropoxiarylderivat.
ATE106401T1 (de) Benzodiazepin-analoge.
EA200100535A1 (ru) Цементирующая композиция и ее применение для цементирования нефтяных скважин или подобных сооружений
EA200101223A1 (ru) Новые соединения, их применение и получение
DK1085896T3 (da) Somatostatinanaloger cykliseret med konformationelt begrænset skelet
PA8556301A1 (es) Compuestos pirimidina de anillo fusionado alquinilado
ATE328005T1 (de) Alle somatostatinrezeptorsubtypen-bindende somatostatinanaloge und deren verwendung
ES2154470T3 (es) Derivados de tetrahidroisoquinolina y su uso farmaceutico.
DK0626381T3 (da) Fremstilling af form 1 ranitidinhydrochlorid
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
ES2152237T3 (es) Pirazolo(4,3-c)piridinas, un procedimiento para su preparacion y su uso como inhibidores de la recaptacion de serotonina.
Hurevich et al. Novel method for the synthesis of urea backbone cyclic peptides using new Alloc‐protected glycine building units
ATE168103T1 (de) Cholecystokininantagoniste
ES2171306T3 (es) Compuesto bajo la forma de isomero geometrico puro o de una mezcla de estos isomeros.
ES2165410T3 (es) Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
EP1123109A4 (en) CONTULAKIN-G, ITS ANALOGS AND USES THEREOF
ES8406458A1 (es) Procedimiento para preparar derivados bencilidenicos sulfurados

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19981001

FG2A Definitive protection

Ref document number: 863897

Country of ref document: ES